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Abstract No standard of care for patients with recurrent
glioblastoma has been defined since temozolomide has
become the treatment of choice for patients with newly
diagnosed glioblastoma. This has renewed interest in the
use of nitrosourea-based regimens for patients with pro-
gressive or recurrent disease. The most commonly used
regimens are carmustine (BCNU) monotherapy or lomus-
tine (CCNU) combined with procarbazine and vincristine
(PCV). Here we report our institutional experience with
nimustine (ACNU) alone (n = 14) or in combination with
other agents (n = 18) in 32 patients with glioblastoma
treated previously with temozolomide. There were no
complete and two partial responses. The progression-free
survival (PFS) rate at 6 months was 20% and the survival
rate at 12 months 26%. Grade III or IV hematological
toxicity was observed in 50% of all patients and led to
interruption of treatment in 13% of patients. Non-hema-
tological toxicity was moderate to severe and led to
interruption of treatment in 9% of patients. Thus, in this
cohort of patients pretreated with temozolomide, ACNU
failed to induce a substantial stabilization of disease in
recurrent glioblastoma, but caused a notable hematotoxic-
ity. This study does not commend ACNU as a therapy of
first choice for patients with recurrent glioblastomas pre-
treated with temozolomide.
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Introduction
The introduction of temozolomide as the standard of care
for patients with newly diagnosed glioblastoma [1] has
resulted in an increased use of temozolomide as the first
chemotherapy of choice for glioma patients in general.
Previously, nitrosourea-based regimens had been consid-
ered the most active chemotherapy for patients with
glioma, although their value had remained controversial
[2]. The British Medical Research Council (MRC) trial had
failed to demonstrate superior activity of PCV added to
radiotherapy compared with radiotherapy alone [3]. The
NOA-01 trial of the Neurooncology Working Group of the
German Cancer Society as well as two smaller series from
Japan had reported very promising median survival data
exceeding 16 months using ACNU-based primary radio-
chemotherapy regimens, but these trials lacked an
appropriate control arm [4–6]. A recent meta-analysis also
proposed a significant survival gain for ACNU in newly
diagnosed high-grade gliomas [7]. The widespread use of
temozolomide in patients with newly diagnosed disease,
mostly glioblastoma, resulted in a reevaluation of nitro-
soureas at progression or recurrence. Larger patient series
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were published for BCNU alone [8] or in combination
with procarbazine and vincristine (PBV) [9] and for PCV
[10, 11]. Here we report our institutional experience with
ACNU, a less well studied nitrosourea compound mainly
used in central Europe and Japan, in the treatment of
patients with progressive or recurrent gliomas.
Methods
We reviewed the records of 32 glioblastoma patients who
were treated with ACNU alone or in combination between
2003 and 2008 after having failed therapy with temozolo-
mide, or suffered recurrence afterwards. All patient charts
were used for an analysis of toxicity. Patients were treated
with ACNU alone (n = 14) or in combination with
teniposide (n = 17) or cytarabine (n = 1). ACNU was
administered in 6-week intervals at 72–90 mg/m2 i.v.
depending on whether it was used alone or in combination
and depending on type and extent, as well as toxicity
associated with prior treatment. Charts were evaluated for
neuroimaging, prior therapy, Karnofsky performance score
(KPS) before ACNU, toxicity and dose of steroids. Tox-
icity was classified according to the common terminology
criteria for adverse events (CTCAE) version 3.0. Response
was assessed retrospectively according to MacDonald cri-
teria [12]. Factors influencing time to progression and
death were analyzed by univariate Log Rank tests with
Kaplan Meier curves and by multivariate COX analysis
with age, gender, KPS, re-resection prior to ACNU and
dexamethasone treatment (yes/no) as covariables. SPSS
software version 15.0 was used for statistical analysis.
Results
Table 1 summarizes essential patient characteristics. Thirty
glioblastoma patients were treated at first and two glio-
blastoma patients at further relapse or progression. Twenty-
six patients died until closure of the database. The median
number of cycles was 2 (range: 1–6). Six patients received
only one cycle, four completed C4 cycles, 20 were on
steroids when starting ACNU. The median dexamethasone
dose of these was 5 mg/day (range 1–18 mg/day).
Toxicity
Sixteen patients (50%) developed CTCAE grade 3/4
hematotoxicity. Twelve patients (38%) displayed CTCAE
grade 3/4 leukocytopenia and nine patients (29%) grade 3/4
thrombocytopenia. Of these 16 patients, nine received a
combination of ACNU and teniposide, in one patient
ACNU was combined with cytarabine and six patients
received only ACNU. The dose of one or more drugs was
reduced because of myelosuppression in 12 patients (38%).
No patient developed neutropenic fever, four required
cytokine support, and four had transfusions at least once.
Other adverse events were documented in seven patients:
nausea (n = 2, CTCAE grade 2), vomiting (n = 1, grade
2), fatigue (n = 1, grade 2), generalized herpes zoster
reactivation (n = 1, grade 3), wound healing disorder
(n = 1, grade 3) and increase of liver enzymes (n = 1,
grade 3). There was no instance of lung fibrosis according
to clinical examinations or spirometry. One patient devel-
oped leukencephalopathic changes documented by MRI
that were considered radiochemotherapy-related, but were
asymptomatic in routine clinical examination without
detailed neuropsychological testing. Chemotherapy was
stopped in seven patients because of adverse events: four
for hematological toxicity, one for generalized herpes
zoster reactivation, one for wound healing disorder and one
for increase of liver enzymes.
Efficacy
Magnetic resonance imaging (MRI) or computed tomog-
raphy (CT) were performed in 2–3 months intervals. There
Table 1 Patient characteristics
Number of
patients
Percentage
(%)
Age (years)
Median 60
Range 33–78
Sex
Male 24 75
Female 8 25
Surgery at relapse prior to ACNU 15 46.9
Extent unknown 2 6.3
Partial resection 10 31.3
Complete resection 3 9.4
Previous (chemo-)therapy 32 100
Temozolomide 32 100
Dose-intensified (1 week on/1 week off) 13 40.6
Standard (5/28) 13 40.6
In combination with CCNU 4 12.5
In combination with cilengitide 2 6.4
In combination with indometacine 1 3.1
Karnofsky performance status at initiation of ACNU
100 5 15.6
90 12 37.5
80 6 18.8
70 8 25
60 1 3.1
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were two partial remissions (PR) (6%), but no complete
remissions (CR). Stable disease (SD) was achieved in five
patients (16%). The median PFS (mPFS) from start of
ACNU was 2.7 months (95% CI: 2.49–2.90). PFS at
6 months (PFS-6) was 20% (two censored cases). The
median OS from the start of ACNU therapy was
6.7 months (95% CI: 3.35–10.1; six censored cases). The
survival rates were 26% at 1 year (five censored cases) and
12% at 2 years (five censored cases) (Fig. 1). Age, KPS
([80 or B80%), co-medication with steroids, a re-resection
or degree of re-resection prior to ACNU chemotherapy
were not associated with time to progression or survival in
a log-rank analysis. None of these factors was identified as
an independent risk factor in a multivariate Cox-regression
analysis. Further, in a univariate log-rank or a multivariate
Cox-regression analysis, the co-medication with teniposide
had no statistical impact on progression-free (P = 0.286
and P = 0.415, Wald = 0.664) or overall (P = 0.736 and
P = 0.949, Wald = 0.04) survival. When forming prog-
nostic subclasses of the patients as suggested by Carson
et al. [13], most patients were classified in group 7
(Table 2). This analysis favours an ACNU-based therapy
in prognostic classes 4–6, but the number of patients in
these subclasses may be too small to draw final
conclusions.
Discussion
The EORTC 26981–22981/NCIC CE3 trial established
temozolomide as the first-line therapy of glioblastoma [1].
There is no such gold standard for the treatment at
progression or recurrence. In this retrospective study, we
analyzed the outcome of 32 patients with recurrent
glioblastoma who were treated with ACNU-based
chemotherapy.
There was a relevant hematotoxicity (CTCAE grade 3/4)
of ACNU-based chemotherapy in 16 patients (50%).
Treatment had to be stopped in three patients because of
non-hematological toxicity. Moreover, the frequency of
adverse events is commonly underestimated in retrospec-
tive series.
In a large meta-analysis, chemotherapy for recurrent
glioblastoma resulted in a PFS of 9 weeks, a PFS-6 of 15%
and a survival rate of 21% at 1 year (OS-1) [14]. A more
recent meta-analysis confirmed these data with a PFS-6 of
16% and an OS-1 of 25% [15]. The latter analysis con-
firmed the importance of PFS-6 as a reliable endpoint for
studies in recurrent gliomas. In the registration trial, tem-
ozolomide given at recurrence in a conventional treatment
schedule induced a progression-free survival of 11 weeks
and a PFS-6 of 21% [16]. A recent phase II study using a
weekly alternating schedule of dose-intensified temozolo-
mide (1 week on/1 week off) led to a median survival of
24 weeks and a PFS-6 of 44% [17]. In the latter study,
patients who had received temozolomide as a first-line
therapy benefited from a dose-intensified re-exposure, too.
Another phase II study evaluated the use of bevacizumab, a
monoclonal antibody to vascular endothelial growth factor,
in combination with irinotecan, a topoisomerase inhibitor
[18, 19]. This study reached a PFS-6 of 46% in patients
with recurrent glioblastoma. Although the role of nitro-
soureas, namely ACNU, BCNU or CCNU in recurrent
Fig. 1 Progression-free and overall survival of 32 patients with
recurrent glioblastoma treated with an ACNU-based chemotherapy (6
and 5 censored cases respectively)
Table 2 Comparison of median survival according to prognostic subgroups as suggested by Carson et al [13]
Prognostic subgroup Carson et al. This study
Patients (n; %) Median survival (months) Patients (n; %) Median survival (months)
4 48 (23%) 10.4 4 (15%) 13.1
5 35 (17%) 5.6 2 (8%) 6.7 and 8.6
6 28 (13%) 6.4 5 (19%) 10.2
7 99 (47%) 4.9 15 (58%) 4.6
Group 4: age \ 50, KPS 90–100. Group 5: age \ 50, KPS 60–80. Group 6: age C 50, no steroids. Group 7: age C 50, with steroids. Six
censored cases
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glioblastoma has been established, most of these data
concern patients that had not been preexposed to tem-
ozolomide. Brandes et al. [9] performed a phase II study
with a combination therapy of procarbazine, BCNU and
vincristine (PBV) and achieved a PFS-6 of 42%. However,
the patients enrolled in this study were chemonaive. In a
retrospective analysis of patients with recurrent glioblas-
toma treated with procarbazine, CCNU and vincristine, a
median PFS of 17 weeks and a PFS-6 of 38% were
observed [11]. In the latter study, 62% of patients had
previous chemotherapy but only 15% had been preexposed
to temozolomide.
In the present study, an ACNU-based chemotherapy
resulted in a PFS-6 of 20%. This PFS rate is poorer than
that observed with the PBV or PCV regimens, but is similar
to that observed with BCNU alone. However, results from
other studies are difficult to compare because of differing
subgroups of patients and risk factor profiles. Patient
characteristics in this study do not suggest a population of
patients excessively enriched for negative prognostic fac-
tors in terms of age or KPS with a preponderance of male
patients (75%). The distribution of patients and the median
OS according to the subgroups proposed by Carson et al.
[13] largely confirms the original publication with a ten-
dency towards a better prognosis in subgroups 4–6.
However, the number of patients in these subgroups was
rather small which limits the interpretation of this finding.
The subgroup 7 resumes most of the patients and the
median survival in this group corresponds well to the data
base. Thus, the relatively poor results in this study could be
due to the fact that the combination partners in the PBV
and PCV regimens contribute to this efficacy or that tem-
ozolomide pre-treated patients are less likely to respond to
nitrosoureas at recurrence. Altogether, treatment results
with ACNU are inferior compared with the recent studies
with bevacizumab/irinotecan [18, 19] or dose-intensified
temozolomide [17] and also showed considerable hemat-
otoxicity. We do not propose that our data exclude a role of
ACNU in certain subgroups of patients or within combined
treatments in recurrent glioblastoma. However, in the era
of temozolomide as the first-line therapy of glioblastoma,
these data can not recommend ACNU as the agent of first
choice at progression or recurrence in terms of tolerability
and efficacy.
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